Before you make a treatment decision
for your advanced cancer patients

Optimize Treatment
for Every Patient

Patients with metastic lung cancer have multiple treatment options. Selecting the right treatment requires comprehensive genomic test results.

Guardant360 has been extensively validated, please see our 80+ publications to learn more.

Move Beyond the Limitations of Tissue Specimens

Lung tissue samples often run out before answering all the clinical questions that guide treatment selection. After the initial diagnosis, additional stains, and immuno-oncology markers, you still need status for EGFR, ALK, ROS1, BRAF, and more.

With Guardant360, you can get comprehensive genomic results from a simple blood draw.

Get Results In Time
For The Next Appointment

Guardant360 fits into your practice,
delivering results in 7 days.

day 1 day 7

See how Guardant360 reports actionable information

Reports

When To Order

Before
First-Line Therapy

When molecular testing is incomplete, unobtainable, or limited.

For instance, when a patient is EGFR and ALK negative but lacks sufficient tissue for ROS1 or BRAF testing

Covered by Medicare

At Progression

To avoid an invasive biopsy when looking for a new genomic target.

To identify potential clinical trials or off-label therapies for patients who have exhausted their standard of care therapy options

Click here for an Advanced Beneficiary Notice (ABN)

Supporting Treatment Selection in NSCLC with Guardant360

Learn why thousands of oncologists have switched to Guardant360

Explore Guardant360 Resources

  • Guardant360 Report Overview
  • See the Guardant360 Gene List
  • 2017 Guardant Health, Inc.
    All Rights Reserved. Legal/Privacy

    x
    x